Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 1603 • ACR Convergence 2025
SGLT-2 Inhibitors are Associated with Lower Risk of End Stage Renal Disease (ESRD) and Lower Mortality in ANCA-associated Vasculitis With Kidney Involvement
Julia Foos¹, Naveed Shah² and Nezam Altorok³, ¹Unversity of Toledo College of Medicine and Life Sciences, Toledo, ²University of Toledo College of Medicine and Life Sciences, Toledo, ³The University of Toledo, Toledo, OH
Background/Purpose: ANCA-associated vasculitis encompasses three main conditions: Granulomatosis with Polyangiitis (GPA, previously called Wegener’s granulomatosis), Eosinophilic Granulomatosis with Polyangiitis (EGPA, previously called Churg-Strauss), and microscopic…
Abstract Number: 0721 • ACR Convergence 2025
Pulmonary Manifestations of Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Mats Junek¹, Sara Choi², Stephanie Garner³, Saara Rawn⁴, David Cuthbertson⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Philip Seo¹², Ulrich Specks¹³, Kenneth Warrington¹³, Gerard Cox¹, Nader Khalidi¹⁴ and Peter Merkel⁸, ¹St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ²Queen's University, Kingston, ON, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴NOSM School of Medicine, Sudbury, ON, Canada, ⁵University of South Florida, Tampa, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Moreland Hills, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD, ¹³Mayo Clinic, Rochester, MN, ¹⁴McMaster University, Hamilton, ON, Canada
Background/Purpose: There is limited knowledge of the epidemiology and complications of pulmonary manifestations in ANCA-associated vasculitis (AAV). This analysis focused describing the range of pulmonary…
Abstract Number: 0724 • ACR Convergence 2025
Risk of Drug Induced Liver Injury with Use of Avacopan in ANCA Vasculitis – Results from Real-World Data
Milad Heydari-Kamjani¹, Elleson Harper² and Haseeb Chaudhary³, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ³Case Western Reserve University, Westlake, OH
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic autoimmune vasculitis. Avacopan, a novel oral C5a receptor inhibitor, has emerged as an adjunct therapy…
Abstract Number: 2519 • ACR Convergence 2025
A Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Avacopan
Shiamak Cooper¹, Asim Khanfar², Yousef al-mabrouk³, Omar Hamdan⁴ and Anthony Ocon⁵, ¹Rochester General Hospital, Irondequoit, NY, ²Rochester General Hospital, Rochester, NY, ³Prince Hanza Hospital, Amman, Jordan, ⁴University of Jordan, Az-Zarqa, Jordan, ⁵Rochester Regional Health, Fairport, NY
Background/Purpose: Avacopan, a C5a receptor inhibitor, is used as an adjunctive treatment for ANCA-associated vasculitis. Previous studies have highlighted its efficacy in reducing glucocorticoid use…
Abstract Number: 2144 • ACR Convergence 2025
The Association Between Age at Diagnosis and Health-Related Quality of Life in ANCA-Associated Vasculitis
Jessica Bloom¹, Kaci Pickett-Nairne², Lori Silveira¹, Cristina Burroughs³, Katrina Bargender⁴, Amy Bolton⁴, Christine Yeung⁴, Jennifer Gordon⁵, Peter Merkel⁶ and Karen James⁷, ¹University of Colorado, Aurora, CO, ²University of Colorado, Denver, ³University of South Florida, Tampa, FL, ⁴Vasculitis Patient-Powered Research Network, Philadelphia, PA, ⁵Vasculitis Foundation, Kansas City, MO, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Utah, Salt Lake City, UT
Background/Purpose: ANCA-associated vasculitis (AAV) is a chronic autoimmune condition that significantly impacts patients’ quality of life. It is unknown whether this impact varies based on…
Abstract Number: 1604 • ACR Convergence 2025
Impact and risk factors of anti-rituximab antibodies in small-vessel vasculitis: a multicenter retrospective study
Lucas Khellaf¹, Raphaele Seror², caterina ricordi³, stephanie chhun⁴, audes gleizes⁴, hervé lobbes⁵, clara pouchelon⁶, marie Charlotte Besse⁷, Jean-Emmanuel Kahn⁸, sabine revuz⁹, Marina Cumin¹⁰, Dimitri Titeca-Beauport¹¹, Matthias Papo⁶, Philippe Rémy⁶, marie Desprets¹², florian garo¹³, Charles Ronsin¹⁴, Salima Hacein-Bey-Abina⁶, Amélie Servettaz¹⁵, Cacoub Patrice¹⁶, Xavier Puéchal¹⁷ and Benjamin Terrier¹⁸, ¹AP-HP, Paris, ²Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ³Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ⁴APHP, Paris, Ile-de-France, France, ⁵Department of Internal Medicine, Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France, ⁶APHP, Paris, France, ⁷CHU Tours, Tours, France, ⁸Ambroise Paré hospital, Boulogne, France, ⁹CHU de la Réunion, Réunion, France, ¹⁰Centre hospitalier de Libourne, Libourne, France, ¹¹CHU Amiens, Amiens, France, ¹²CH Chôlet, Cholet, France, ¹³CHU Nîmes, Nîmes, France, ¹⁴CHU Nantes, Nantes, France, ¹⁵Internal Medicine, CHU Reims, Reims, France, ¹⁶Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ¹⁷Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ¹⁸Cochin Hospital, Paris, France
Background/Purpose: Small vessel vasculitis mainly includes ANCA-associated vasculitis (AAV) and cryoglobulinemic vasculitis (CV), leading to significant organ damage. Rituximab (RTX), an anti-CD20 monoclonal antibody, has…
Abstract Number: 0720 • ACR Convergence 2025
Current State of Racial, Ethnic, Sex, and Geographical Diversity in ANCA-associated vasculitis and Giant Cell Arteritis Trials
Manuel Carpio Tumba¹, Aida Mohamadi², Diana Louden³, Victor Pimentel-Quiroz⁴, Michael Putman⁵, Didem Saygin⁶, Raisa Lomanto Silva⁷ and Sebastian E Sattui⁸, ¹University of Pittsburgh, Pittsburgh, PA, ²Tehran University of Medical Sciences, Tehran, Iran, ³University of Washington, Seattle, WA, ⁴Universidad Científica del Sur, San Isidro, Peru, ⁵The Medical College of Wisconsin, Milwaukee, WI, ⁶Rush University Medical Center, Chicago, IL, ⁷Massachusetts General Hospital, Boston, MA, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Randomized controlled trials (RCTs) generate unbiased efficacy estimates and are required for regulatory approval. Understanding the degree to which they include racial, ethnic, sex,…
Abstract Number: 0725 • ACR Convergence 2025
Sinonasal Symptom Profiles Associated with Disease Activity in an International Cohort of Patients with ANCA-Associated Vasculitis
Rennie Rhee¹, Christine Yeung², Darrin White³, Mary Gibson³, Jessica Nguyen⁴, Cristina Burroughs⁵, Jennifer Gordon⁶, Noam A. Cohen⁴, Jeffrey Morris⁴ and Peter Merkel¹, ¹University of Pennsylvania, Philadelphia, PA, ²Vasculitis Patient-Powered Research Network, Philadelphia, PA, ³². Patient Research Partner, Vasculitis Patient-Powered Research Network, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵University of South Florida, Tampa, FL, ⁶Vasculitis Foundation, Kansas City, MO
Background/Purpose: Sinus and nasal symptoms are common and associated with a higher risk of relapse in patients with ANCA-associated vasculitis (AAV). Previously, our group found…
Abstract Number: 2520 • ACR Convergence 2025
Evolution in Risk Stratification for Renal Outcomes in ANCA-Associated Vasculitides Using Established Scores and Histopathological Criteria in a Large European Cohort
Stefan Krämer¹, Kristian Vogt², Martin Busch³, Tobias Schmitt⁴, Raoul Bergner⁵, Sebastian Mosberger⁵, Thomas Neumann⁶, Teresa Schreibing¹, Fabian Schumbrink¹ and Thomas Rauen², ¹Department of Internal Medicine II, RWTH University Hospital Aachen, Aachen, Germany, ²Department of Internal Medicine II, RWTH University Hospital AachenMedicine II, Aachen, Germany, ³Department of Internal Medicine III, University Hospital, Friedrich-Schiller University, Jena, Jena, Germany, ⁴University Hospital Jena, Friedrich-Schiller University, Department of Internal Medicine III, Jena, Germany, ⁵Department of Internal Medicine A, Nephrology and Rheumatology, Municipal Hospital Ludwigshafen, Ludwigshafen, Germany, ⁶Department of Rheumatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Glomerulonephritis is a common and threatening manifestation in ANCA-associated vasculitis (AAV). To assess the risk of end-stage kidney disease (ESKD), various scores have been…
Abstract Number: 1769 • ACR Convergence 2025
Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy
Christian Pagnoux¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Ulrich Specks⁸, Benjamin Terrier⁹, Lena Börjesson Sjö¹⁰, Priya Jain¹¹, Aadarsh Lal¹², Sofia Necander¹³, Claire Walton¹⁴, Michael Wechsler¹⁵ and Peter Merkel¹⁶, ¹Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mayo Clinic, Rochester, MN, ⁹Cochin Hospital, Paris, France, ¹⁰Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹²Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹³Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁴Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁵Department of Medicine, National Jewish Health, Denver, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Results from the ongoing open-label extension (OLE) of the MANDARA trial (NCT04157348) have demonstrated the efficacy of two years of anti-interleukin-5/receptor (anti-IL-5/R) therapies in…
Abstract Number: 1601 • ACR Convergence 2025
Obinutuzumab Induces and Maintains Remission in Refractory or Relapsing ANCA-Associated Vasculitis – A Case Series
Helen Au¹, Christian Löffler², Hartmut Mahrhofer¹, Bastian Walz¹ and Bernhard Hellmich¹, ¹Klinik für Innere Medizin, Rheumatologie und Immunologie, medius Klinik Kirchheim, Kirchheim unter Teck, Germany, ²Medizinische Klinik V, Nephrology, Endocrinology, Hypertensiology and Rheumatology, Universitaetsmedizin Mannheim, University of Heidelberg, Mannheim, Germany
Background/Purpose: B-cell depletion with anti-CD20 therapy is the current cornerstone of management in organ- or life-threatening ANCA-associated vasculitis (AAV). Guidelines recommend the use of rituximab…
Abstract Number: 0717 • ACR Convergence 2025
Circulating Bacterial sRNAs are Altered in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Christopher Xavier¹, Kevin Byram², Carol Langford³ and Michelle Ormseth⁴, ¹Meharry Medical College, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Cleveland Clinic, Moreland Hills, OH, ⁴Vanderbilt University Medical Center, Nashville
Background/Purpose: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (AAV) is an autoimmune disease causing small vessel inflammation. Underlying mechanisms of disease are unclear, but the human microbiota may…
Abstract Number: 0421 • ACR Convergence 2025
Inflammatory Orbital Diseases: Pediatric Case Series From a Tertiary Care Center
Rasha Elrefai¹, Katherine Williams² and Hannah Bradfield³, ¹Baylor College of Medicine, Houston, TX, ²Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Orbital inflammatory diseases in the pediatric population present diagnostic and therapeutic challenges due to variable clinical manifestations, limited prospective data, and lack of standardized…
Abstract Number: 2518 • ACR Convergence 2025
Impact of psychiatric comorbidity on disease outcomes in ANCA-associated vasculitis: A multi-center retrospective cohort study
Saloni Patel¹, Brendan Denvir², Maria Kaltchenko¹, Aaron Bao³, Varsha Simha¹, Michael Cammarata⁴ and Jun Kang⁵, ¹Johns Hopkins University School of Medicine, Baltimore, ²Johns Hopkins, Baltimore, MD, ³Johns Hopkins School of Medicine, Baltimore, MD, ⁴Johns Hopkins, Phoenix, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic small vessel vasculitis associated with significant morbidity and complex care needs across a broad demographic…
Abstract Number: 1767 • ACR Convergence 2025
Identification of C3 complement fragments in lesional tissues in ANCA-associated vasculitis
Claire Galand¹, Fei Liu², Katherine Vernon², Ravi Vats², Christine Lian³, V. Michael Holers⁴, H. Terence Cook⁵, David Cuthbertson⁶, Nader Khalidi⁷, Curry Koening⁸, Carol Langford⁹, Carol McAlear¹⁰, Paul Monach¹¹, Christian Pagnoux¹², Jason Campagna², Shelia Violette² and Peter Merkel¹⁰, ¹Q³² Bio Inc,, Waltham, MA, ²Q³² Bio Inc, Waltham, MA, ³Department of Pathology, Brigham & Women’s Hospital/Harvard Medical School, Boston, MA, ⁴University of Colorado Anschutz Medical Campus, Aurora, ⁵Department of Immunology and Inflammation, Imperial College London, London, United Kingdom, ⁶University of South Florida, Tampa, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Texas Dell Medical School, Austin, TX, ⁹Cleveland Clinic, Moreland Hills, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹VA Boston Healthcare System, Boston, MA, ¹²Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: One proposed mechanism of tissue damage in ANCA-associated vasculitis (AAV) is the formation of neutrophil extracellular traps (NETs) during extravasation of neutrophils into and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].